Evidence map›Paper›PMID 28637868›Full record

ArticleThe Journal of biological chemistry2017

Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

Sheng Tan, Keshuo Ding, Qing-Yun Chong, Junsong Zhao, Yuan Liu, Yunying Shao, Yuanyuan Zhang, Qing Yu, Zirui Xiong, Weijie Zhang and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. RNA binding proteins in cancer chemotherapeutic drug resistance.Frontiers in cell and developmental biology · 2024
    Review
  7. Landscape of NcRNAs involved in drug resistance of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. FXR1 promotes the malignant biological behavior of glioma cells via stabilizing MIR17HG.Journal of experimental & clinical cancer research : CR · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Sheng TanFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Keshuo DingFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Qing-Yun Chongthe Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Singapore 117599, Singapore.
Junsong ZhaoFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Yuan LiuFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Yunying ShaoFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Yuanyuan ZhangFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Qing YuFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Zirui XiongFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Weijie ZhangFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Min ZhangFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Gaopeng LiFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Xiaoni LiFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Xiangjun KongFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Akhlaq AhmadFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
Zhengsheng Wuthe Department of Pathology, Anhui Medical University, Meishan Road, Hefei 230032, China.
Qiang Wuthe Department of Pathology, Anhui Medical University, Meishan Road, Hefei 230032, China.
Xiaodong Zhaothe School of Biomedical Engineering, Bio-ID Center, Shanghai Jiao Tong University, Shanghai 200240, China, and.
Peter E Lobiethe Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Singapore 117599, Singapore, csipel@nus.edu.sg.
Tao ZhuFrom the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China, zhut@ustc.edu.cn.
University of Science and Technology of China · CNHefei National Center for Physical Sciences at Nanoscale · CNAnhui Medical University · CNNational University Cancer Institute, Singapore · SGShanghai Jiao Tong University · CNTsinghua–Berkeley Shenzhen Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tamoxifen-resistant (TAMR) estrogen receptor-positive (ER+) breast cancer is characterized by elevated Erb-B2 receptor tyrosine kinase 2 (ERBB2) expression. However, the underlying mechanisms responsible for the increased ERBB2 expression in the TAMR cells remain poorly understood. Herein, we reported that the ERBB2 expression is regulated at the post-transcriptional level by miR26a/b and the RNA-binding protein human antigen R (HuR), both of which associate with the 3'-UTR of the

Indexed as

Drug Resistance, Neoplasm3' Untranslated RegionsAntineoplastic Agents, HormonalBreast NeoplasmsCell Line, TumorCell ProliferationCleavage Stimulation FactorELAV-Like Protein 1Erb-b2 Receptor Tyrosine KinasesFemaleHumansMicroRNAsMutationNeoplasm ProteinsPolyadenylationResponse Elements3' Untranslated RegionsAntineoplastic Agents, HormonalCleavage Stimulation FactorCSTF2T protein, humanELAVL1 protein, humanELAV-Like Protein 1ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMicroRNAsMIRN26 microRNA, humanNeoplasm ProteinsRNA-Binding ProteinsRNA, MessengerRNA, NeoplasmTamoxifenbreast cancercancer therapyELAV-like protein 1 (HuR (human antigen R))ERBB2microRNA (miRNA)tamoxifentumor cell biology

Identifiers

PMID28637868
PMCPMC5566515
OpenAlexW2645948085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.